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Background: Over the past 50 years, there has been an increase in the utilization of prescribed, over-the-counter
(OTC) medications, and natural health products. Although it is known that medication use is common among older
persons, accurate data on the patterns of use, including the quantity and type of medications consumed in a generally
healthy older population from a Canadian perspective are lacking. In this study, we study the pattern of medication use in
a sedentary but otherwise healthy older persons use and determined if there was an association between medication use
and aerobic fitness level.
Methods: All participants enrolled in the Brain in Motion study provided the name, formulation, dosage and frequency of
any medications they were consuming at the time of their baseline assessment. Maximal aerobic capacity (VO2max) was
determined on each participant.
Results: Two hundred seventy one participants (mean age 65.9 ± 6.5 years; range 55–92; 54.6% females) were enrolled.
Most were taking one or more (1+) prescribed medication (n = 204, 75.3%), 1+ natural health product (n = 221, 81.5%)
and/or 1+ over-the-counter (OTC) drug (n = 174, 64.2%). The most commonly used prescribed medications were HMG-
CoA reductase inhibitors (statins) (n = 52, 19.2%). The most common natural health product was vitamin D (n = 201, 74.
2%). For OTC drugs, non-steroidal anti-inflammatories (n= 82, 30.3%) were the most common. Females were more likely
than males to take 1+ OTC medications, as well as supplements. Those over 65 years of age were more likely to consume
prescription drugs than their counterparts (p≤ 0.05). Subjects taking more than two prescribed or OTC medications were
less physically fit as determined by their VO2max. The average daily Vitamin D intake was 1896.3 IU per participant.
Conclusions: Medication use was common in otherwise healthy older individuals. Consumption was higher among
females and those older than 65 years. Vitamin D intake was over two-fold higher than the recommended 800 IU/day for
older persons, but within the tolerable upper intake of 4,000 IU/day. The appropriateness of the high rate of medication
use in this generally healthy population deserves further investigation.
Keywords: Natural Health Products, Prescription drugs, Geriatrics, Polypharmacy* Correspondence: poulin@ucalgary.ca
1Department of Physiology and Pharmacology, Hotchkiss Brain Institute,
Cumming School of Medicine, University of Calgary, HMRB-210, 3330
Hospital Drive NW, Calgary, AB T2N 4N1, Canada
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Flow chart outlining the phases of the BIM study. Medication
use was obtained at the time of baseline assessment (Pre-intervention
Phase 1A)
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Approximately 60% of older persons live a sedentary
lifestyle and do not engage in sufficient physical activ-
ity to acquire health benefits [1]. Physical inactivity is
a known modifiable risk factor for cerebrovascular
disease and dementia [2, 3]. The doubling of the
older population over the next 25 years will be asso-
ciated with increases in the numbers of those with
cognitive decline and dementia [4].
Between 1997 and 2007, Canada was second to the
United States in the growth of prescription drug expend-
iture per capita [5]. Annual growth was 10.1%, and by
the end of this period, prescription drug expenditures
had become the second largest component of health
care spending in Canada [5]. Heavy use of pharmaceuti-
cals becomes particularly marked at older age ranges
[6–9]. Eighty three percent of community-dwelling
Canadians 65–79 years of age in 2007–2011 were tak-
ing prescription medication with 33% taking 5 or
more [6]. In addition to prescribed medications, there
is a widespread use of over-the-counter (OTC), diet-
ary supplements, and alternative agents even within
healthy populations [5, 8, 10, 11]. The use of comple-
mentary and alternative medicine (CAM), defined by
Health Canada as being for the “diagnosis, treatment
and/or prevention that complements mainstream
medicine”, is very common with a large proportion of
adults using natural health products. Although the
rise in the use of pharmaceuticals is well known, the
pattern of the combined use of the various types of
medications being consumed by individuals is less
well defined. Few studies have described medication
use in a unique population composed of otherwise
healthy middle-aged and older sedentary Canadians.
The Brain in Motion (BIM) study is a quasi-
experimental prospective cohort study designed to deter-
mine the effect of aerobic exercise for six months on
cognitive function and cerebrovascular physiology in the
sedentary older adults enrolled in our study. Because of
the study’s exclusionary criteria, the study population
was anticipated to be healthier than the general popula-
tion of Canadians of a similar age. The purpose of this
study was to describe the pattern of medication use by
study participants at baseline prior to the exercise inter-
vention component of the BIM study. Furthermore, we
examined whether there was an association between par-
ticipants’ fitness levels and the use of medications. Given
their health status, we hypothesized these participants
would show lower levels of medication consumption
compared with similarly aged Canadians.
Methods
BIM is an 18-month quasi-experimental prospective
cohort study examining the role of exercise on cognitivefunction and cerebrovascular physiology [12]. The study
consisted of three six-month phases: 1) pre-intervention
phase; 2) aerobic exercise intervention phase; and 3)
post-intervention phase (Fig. 1) [12]. The Conjoint
Health Research Ethics Board at the University of
Calgary approved the study, and participants provided
written informed consent prior to participating in the
study. Medication use was obtained at the time of the
baseline assessment (Pre-intervention Phase 1A) (Fig. 1),
during which time participants were asked to list the
name, formulation, dosages, and frequency of consump-
tion of all medications and supplements that they were
currently taking. These agents were then categorized as
prescribed (i.e., require a prescription to be obtained
from their physician) and non-prescribed, which were
further sub-categorized as OTC medications (i.e., avail-
able for purchase without a prescription) as natural
health products (which included vitamins and minerals,
herbal remedies, homeopathic medicines, traditional
medicines, or probiotics). We defined drug use intensity
as the mean number of medications consumed per per-
son. Years of education were also recorded at baseline,
and defined as total years completed in a formal educa-
tion program starting with primary (elementary) school.
Recruitment and eligibility
Subjects were recruited from the City of Calgary be-
tween 2009 and 2014 through media, poster and news-
paper advertisements. Potential participants provided
informed written consent prior to enrollment into the
study. During an initial phone interview, interested par-
ticipants were assessed for their eligibility based on pre-
determined inclusion and exclusion criteria, as discussed
below. Potential participants who successfully completed
Table 2 Baseline prescribed medication use among participants
(N = 271) enrolled in the Brain in Motion study (listed alphabetically)
Prescribed medications % total participants
(number)
Drugs used for diabetes 4.4% (12)
Anticonvulsant 3.0% (8)
Antihypertensive/ cardiovascular agents
bACE Inhibitor 8.9% (24)
Angiotensin Receptor blocker 12.5 (34)
Beta blocker 3.7% (10)




Opioid Analgesic 3.3% (9)
Antidepressant 14.4% (39)
Benign Prostrate Hyperplasia Agent
Alpha blocker 2.6% (7)
Cholesterol lowering agent






Proton Pump Inhibitor 7.4% (20)
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a 60-min on-site assessment of study eligibility [12].
Participation in the study required approval by their at-
tending primary care physician, and physicians affiliated
with the study examined all subjects at entry to ensure
their safety [12].
Subjects
Subjects were sedentary men and women aged 55 years
and older. Sedentary behaviour was defined as, engaged
in less than 30 min of moderate exercise 4 days per week
or 20 continuous minutes of vigorous exercise twice
weekly. Inclusion criteria included: Body Mass Index of
less than 35 kg/m2; ability to walk independently outside
and up and down at least 20 stairs; non-smoker for at
least 12 months; not suffering from an active cardiovas-
cular, cerebrovascular, or pulmonary condition that
would preclude their ability to safely exercise; no major
surgery or trauma within the last 6 months; free from a
debilitating neurological condition; and, a Montreal Cog-
nitive Assessment score of 24 or greater [12].
Maximal aerobic capacity
At baseline, subjects underwent assessments of fitness
levels by a maximal aerobic capacity (VO2max) test. This
was used as our measure of fitness. The VO2max test was
conducted on a motorized treadmill and follows the Bruce
protocol [13]. A plateau in oxygen uptake with increasing
work rate (<2 mL/kg/min), a respiratory exchange ratio of
at least 1.15, and age-predicted maximal heart rate (210-
(age X 0.65)) were used as criteria for stopping the test (as
recommended by the Canadian Society for Exercise
Physiology [14] and American Thoracic Society [15]. Out-
come measures for the VO2max test include oxygen up-
take, carbon dioxide production, and ventilation (tidal
volume and breathing frequency) [12].
Data analysis
Categorical proportions were compared using Fisher’s
exact of Chi2 tests. Relationships between VO2max andTable 1 Baseline characteristics of subjects enrolled in the Brain
in Motion study
Demographics Number of subjects
(N = 271)
Average age ± SD 65.9 ± 6.5
% (number) female sex 54.6% (148)
Average number of years of education ± SD 15.9 ± 2.7
Total % (number) of participants consuming
1+ prescribed medication at baseline
75.3% (204)
Total % (number) of participants consuming
1+ natural health product at baseline
81.5% (220)
Total % (number) of participants consuming
1+ over-the-counter medication at baseline
64.2% (174)medication usage were analyzed using a generalized lin-
ear model, whereby we determined the combined effects
of sex and medication usage on VO2max when control-
ling for age.
Results
Among the 271 subjects (mean [SD] age 65.9 ± 6.5 years,
54.6% females) enrolled in the Brain In Motion study
who completed their baseline assessment (Table 1), mostSleep aids








bACE Angiotensin Converting Enzyme
NSAID Non-Steroidal Anti-Inflammatory Drug
HMG-CoA 3-Hydroxy-3-Methyl-Glutaryl-CoA
aThese include only prescribed NSAIDs
Table 4 Vitamin D analysis in 201 participants on Vitamin D
supplements. This analysis does not include dietary intake
Vitamin D analysis, N = 201 (per day)
Recommended intake (IU)* 800
Average intake (IU) 1896.3
Median intake (IU) 1400
Minimum dosage (IU) 200
Maximum dosage (IU) 12000
% of subjects taking > 800 IU (n) 79.1 (159)
% of subjects taking≥ 2000 IU (n) 41.8 (84)
% of subjects taking≥ 4000 IU (n) 9.5 (19)
*IU International Units
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(75.3%), natural health product (81.5%), and/or OTC
drug (64.2%). The most commonly prescribed medica-
tions were cholesterol lowering agents (specifically
HMG-CoA reductase inhibitors or statins) and thyroid
replacement therapy (Table 2). Vitamin D was the most
common natural health product consumed, while non-
steroidal anti-inflammatories (NSAIDs) were the most
common OTC medication reported (Table 3). The aver-
age daily vitamin D intake was 1896 IU per participant
with 42% of participants taking more than 2000 IU per
day and 10% above 4000 IU (Table 4).
More females than males were taking one or more
OTC medications (70% women v 57% men). Natural
health products (58% women v 42% men) and prescribed
medications (78% women v 72% men) use was similar
between the sexes. Older subjects (age > 65 years) were
more likely to be taking at least one medication in all
three categories and had a higher prescribed drug use
intensity (mean number of medications consumed per
person) (Table 5). When controlling for age, men and
women taking more than two prescribed or OTCTable 3 Baseline supplement, natural produce and over-the-counter m
in motion study
Natural health products % Total participants (number)
Antioxidants 4.8% (13)
Coenzyme Q10 7.0% (19)








Other (e.g. magnesium, zinc) 16.6% (45)
Multi-vitamins 33.9% (92)
Omega 3 37.6% (102)
Plant Oil 4.1% (11)
Probiotics 4.4% (12)
Vitamins
Vitamin D* 74.2% (201)
Vitamin C 15.9% (43)
Vitamin E 7.7% (21)
B-complex 18.1% (49)
Other (e.g. A, K) 1.8% (5)
Other 32.5% (88)
None 45.8% (124)
*Includes 180 unique participants taking a vitamin D supplement and 21 taking mumedications were less physically fit, as determined by
their VO2max measurements (Table 6).
Discussion
This study presents data on the pattern of medication
use in sedentary but otherwise generally healthy middle-
aged and older adults. According to the Chief Public
Health Officer’s Report on the State of Public Health inedication use among participants (N = 271) enrolled in the brain









ltivitamins not on a separate vitamin D supplement
Table 5 Number (%) of people taking prescribed medications
according to the age group and number of medications per










0 30.7 (39) 19.4 (28) 0.019
1 22.8 (29) 22.2 (32)
2 20.5 (26) 20.8 (30)
3 14.2 (18) 13.2 (19)
4 7.9 (10) 8.3 (12)
5 or more 3.9 (5) 16.0 (23)
*Fisher’s exact test
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Canadian older persons (i.e., 65 or more years of age)
suffered from cardiovascular disease and over 4% from
stroke. Those with active cardiovascular or debilitating
neurological conditions were excluded from entry into
our study, which also recruited a number of individuals
less than 65 years of age [16]. While 62% of Canadian
seniors reported being in very good functional health,
nearly one-quarter of them had difficulties with activities
such as walking, communicating, seeing, and climbing
stairs [16]. BIM participants had to be able to function
independently without difficulties. They were able to
perform moderate physical activity three times a week,
for the 6-month intervention period, and also underwent
demanding physiological testing (such as VO2max tests)
a number of times during the 18-month study.
Most subjects (75.3%) were taking at least one pre-
scription drug at baseline (most commonly used were
cholesterol lowering agents and L-thyroxine) (Table 2).
Canadians in general are heavy users of prescribed medi-
cations. A total of $27,734 million (or $795.32 per
capita) was spent on prescription drugs nationally in
2012 [6, 17]. In 2012 the most common prescription
medication used by older persons in Canada were statins
(46.6%), followed by angiotensin-converting-enzyme
(ACE) inhibitors (28.4%) and proton pump inhibitors




N VO2maxMean(SD) P-value N VO2
0 57 28.36(6.02)* - 24 24.5
1 65 27.23(5.63)* >0.05a 35 24.6
2 53 25.28(4.69) 0.03b 29 23.5
>3 86 23.72(4.36)* <0.001c 53 22.2
Sex difference: *P < 0.05
N Number of participants in each category
P-values: adifference between 0 medication and >3 medications; bdifference betwee
>3 medicationstaking statins, their rate of use (19.2%) was less than half
of that reported for the general older population
(Table 2). Use of ACE inhibitors (8.9%) and proton
pump inhibitors (7.4%) was also substantially lower than
that reported for the general older Canadian population
[9]. This is consistent with our impression that study
participants were generally healthier than the older
Canadian population. Similar to other studies female sex
and older age were associated with a greater intensity of
prescribed medication use [6–9].
A majority of subjects were taking at least one natural
health product (81.5%) or OTC medication (64.2%)
(Table 1). NSAIDs were the most commonly used OTC
medication (30.3%) in our study. One of the commonest
reason for supplement use is a desire to improve or
maintain overall health [19]. There are limited data to
support the health benefits of supplements and natural
products in generally healthy individuals, and there is a
potential, albeit small, of risk of harm with their use. Ad-
verse drug effects and drug-drug interactions can occur
[20–33]. Supplements can reduce the efficacy of specific
medications [10, 22–25, 28–37] while the consumption
of multiple agents concurrently is associated with a
higher risk of non-adherence [35]. Although prescription
medications have a higher likelihood of side effects,
there is greater regulatory oversight. Since these medica-
tions require a prescription, physicians and pharmacists
should be informing patients of potential side effects
and monitoring for them. With OTC medications the at-
tending physician may be unaware of their use (which is
commonly the case) [29] with no monitoring for side
effects and assessment for potential interactions. Con-
sumption of these agents tends to increase with age [36].
The use of medications (prescription and OTC) is asso-
ciated with a decrease in the fitness levels of participants
(Table 6). Because of the observational nature of this
study no conclusions about a causal relationship can be
made. Possibly the presence of various clinical condi-
tions alone or in combination with other ones are asso-
ciated with both medication use and worse fitness levels.
Nearly three-quarters of our study population were
taking vitamin D. The average daily intake was 1896 IUnts consuming OTC and prescription medication
Male
maxMean(SD) P-value N VO2maxMean(SD) P-value
9(5.17) - 33 31.10(5.08) -
(4.94) >0.05a 30 30.30(4.82) >0.05a
5(4.04) 0.04b 24 27.36(4.63) 0.04b
6(3.67) 0.005c 33 26.06(4.40) <0.001c
n 1 medication and >3medications; cdifference between 2 medications and
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2000 IU per day and 10% above 4000 IU (Table 4).
Nearly half (47.5%) of the Canadian population is report-
edly taking supplemental vitamin D [38] at a median
dose of 400 IU/day [39]. Factors reported to be associ-
ated with a greater likelihood of use included increasing
age, female sex, English language, diagnosis of osteopor-
osis, perceived lactose intolerance, and university educa-
tion [38]. In postmenopausal women and men above 50,
vitamin D and calcium supplementation might lead to
increased bone density and reduce the risk of falls and
hip and non-vertebral fractures [40] though these claims
are controversial [41, 42]. Adults over 50 years of age
are at a moderate risk of vitamin D deficiency. Vitamin
dosages as high as 2000 IU/day can safely be given with-
out the need for any monitoring [39, 43]. While some
feel doses up to 4000 IU/day are safe [44], others believe
that doses above 2000 IU/day should be supervised be-
cause of potential risks of hypercalcemia and renal dys-
function [40, 43].
Our study had a number of limitations. We did not
know the indications for the medications taken, or
whether they were effective for the indication of their use.
We were unable to determine whether OTC medications
were recommended by a physician or taken without their
advice or knowledge. We did not assess adherence. To-
gether, this means that we cannot comment on the appro-
priateness of the medications being taken. Our emphasis
was on describing overall use rather than understanding
their indications. Finally, given the strict inclusion criteria
for the Brain in Motion study, our findings relating to the
medication use in this group, may not be representative of
the general population.
Conclusion
This study showed high medication use (prescribed, OTC,
and natural health products) in a generally healthy group
of middle-aged and older Canadians. Consumption was
higher in females, and amongst those older than 65 years.
Higher medication usage was associated with a lower fit-
ness level. Rate of medication use was lower than that of
the general older Canadian population. The appropriate-
ness of this the high rate of medication use in this gener-
ally healthy population deserves further investigation.
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